The inhibition of S100A8/S100A9 by Tasquinimod, a small oral inhibitor, ameliorates the MPN phenotype and fibrosis, likely by affecting the mutated hematopoietic clone and MSC fibrotic transformation [186]. Here, S100A9 is linked to myeloproliferative disorder.